SecBot SecBot
Insider Cluster (5 insiders) ·Filed Jul 2, 2026

KYMR

Kymera Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago
Insider cluster: 3 insiders, $13.2M total
Actionable Insight ▼ Bearish

The CEO and CFO both exercised options and sold large blocks of shares within the same week, a pattern that often signals a desire to lock in gains after a significant stock run-up. While the dollar amount is modest relative to market cap, the concentration of C-suite selling is a cautionary signal. Monitor for any upcoming catalyst (data readout, partnership, or offering) that might have prompted the timing. The stock's 93% analyst bullish consensus and strong recent performance suggest the selling may be liquidity-driven, but the cluster warrants a watchful stance.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$114.76
T+0 close · Jul 2, 2026 · via day close
Latest settled
−3.70%
T+60 · $110.51
Vs SPY
−5.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $114.76entry
  2. T+1 · 4mo ago +3.90%α +4.38% · $119.24
  3. T+5 · 4mo ago −3.80%α −3.52% · $110.40
  4. T+20 · 4mo ago −12.59%α −13.44% · $100.31
  5. T+60 · 7w ago −3.70%α −5.42% · $110.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three Kymera insiders, including CEO Nello Mainolfi, CFO Bruce Jacobs, and a director, sold a combined ~$13.2M in open-market shares over a 7-day window ending July 1, 2026. CEO Mainolfi alone sold ~$9.2M after exercising options, while CFO Jacobs sold ~$9.9M. The cluster represents ~0.14% of Kymera's $9.4B market cap, falling in the modest-to-notable proportionality band. While the dollar value is not overwhelming relative to market cap, the concentration of C-suite selling, particularly the CEO and CFO both selling within days of each other, warrants attention, especially given the stock's strong recent performance and the company's 93% analyst bullish consensus.

Key Financial Metrics

Direction
selling
Total Value
$19.4M
Insiders
5

Key Facts

  • CEO Nello Mainolfi sold ~$9.2M in open-market shares on July 1, 2026, after exercising options.
  • CFO Bruce Jacobs sold ~$9.9M in open-market shares on June 30, 2026, after exercising options.
  • Director Bruce Booth sold ~$281K in open-market shares on June 29, 2026.
  • Total insider selling in the cluster: ~$19.4M (combining the 7-day window and the prior week's data).
  • The cluster represents ~0.21% of Kymera's $9.4B market cap, falling in the modest-to-notable proportionality band.
  • CEO and CFO both exercised options and immediately sold a large portion of the resulting shares, a pattern consistent with tax- and liquidity-driven selling, but the concentration and timing are notable.

Financial Impact

Total insider selling of ~$19.4M over a 7-day window, representing ~0.21% of Kymera's $9.4B market cap.

insider ownershipfloat

Risk Factors

  • CEO and CFO both sold large blocks after option exercises, potential signal of peak valuation sentiment.
  • Total insider selling of ~$19.4M in a 7-day window is notable for a $9.4B market cap company.
  • Stock has rallied significantly in recent months; insiders may be taking profits near a perceived top.
  • No insider buying to offset the selling, one-sided selling cluster.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KYMR-1783060609015

Track record

37 reports on KYMR

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 8 of 13 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Viewing Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026